U.S. markets open in 1 hour 7 minutes
  • S&P Futures

    3,678.00
    -31.00 (-0.84%)
     
  • Dow Futures

    29,456.00
    -213.00 (-0.72%)
     
  • Nasdaq Futures

    11,293.50
    -83.25 (-0.73%)
     
  • Russell 2000 Futures

    1,670.40
    -15.70 (-0.93%)
     
  • Crude Oil

    77.82
    -0.92 (-1.17%)
     
  • Gold

    1,649.80
    -5.80 (-0.35%)
     
  • Silver

    18.72
    -0.19 (-1.00%)
     
  • EUR/USD

    0.9657
    -0.0031 (-0.32%)
     
  • 10-Yr Bond

    3.6970
    0.0000 (0.00%)
     
  • Vix

    32.41
    +5.06 (+18.50%)
     
  • GBP/USD

    1.0801
    -0.0056 (-0.52%)
     
  • USD/JPY

    143.9930
    +0.6730 (+0.47%)
     
  • BTC-USD

    18,875.56
    -258.70 (-1.35%)
     
  • CMC Crypto 200

    432.41
    -12.13 (-2.73%)
     
  • FTSE 100

    6,964.54
    -54.06 (-0.77%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

·1 min read

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.

  • Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.

  • The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.

  • AVA-011 is currently at the IND-enabling process development stage.

  • Related: Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights.

  • The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.

  • Price Action: AVCO shares are down 1.18% at $0.87 during the market session on the last check Monday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.